



**Rett syndrome (RTT)** is a rare autosomal dominant neurodevelopmental disorder arising from spontaneous mutations in the **MECP2** gene on the X chromosome. Individuals with RTT experience severe neurological complications including progressive loss of motor skill, speech, and behavioral functions. To identify potential therapeutics for treating Rett syndrome, we generated and screened iPSC-derived microBrain 3D spheroids from healthy control and patient donors to identify compounds and target pathways that rescued the patient derived microBrain 3D-RTT phenotype.


microBrain 3D and microBrain 3D-RTT show similar structural and cellular composition.




Phenotypic differences were identified between healthy and disease spheroids. RTT spheroids showed altered electrophysiology and decreased neurite outgrowth.




Phenotypic screening of microBrain 3D-RTT spheroids identified compounds that 'rescued' the disease phenotype.



Hit identification and prioritization by multiparametric analysis allows differentiation between compounds with no, partial, and near complete phenotypic rescue.



Multiple target pathways and potential development approaches were identified with the native human neurobiology of microBrain 3D-RTT.



#### microBrain 3D technology

- Enables iPSC-based disease modeling and high throughput screening.
- Provides native human biology to uncover multiple potential therapeutic pathways.
- Accelerates drug discovery by combining disease models and HTP screening in a single, relevant human-based preparation.

For more information on this or other custom disease models, please contact us at [info@stemonix.com](mailto:info@stemonix.com)